Abstract
Objectives. To evaluate the in vitro virucidal effect of the combination of cetylpyridinium chloride (CPC) and benzydamine hydrochloride (BH) as a throat lozenge against the novel SARS-CoV-2. Material and methods. The study evaluated the viral presence and titre in cell cultures by using SARS-CoV-2 virus incubated for 1, 5, 15 minutes, with three different concentrations of three different active substances (CPC, free BH/ CPC, BH/CPC lozenge). The titre of the virus was expressed as TCID50/ml calculated with the Spearman-Kärber method. Outcomes. The faster virucidal effect in high concentration was seen in the combination BH/CPC as throat lozenge when compared to CPC as free active substance. A reduction of the virus concentration was seen, at 15 minutes contact, in all three concentrations. Conclusions. There is a strong virucidal effect a throat lozenge with fixed combination of cetylpyridinium chloride and benzydamine hydrochloride on the novel coronavirus.
Highlights
Respiratory tract infections (RTI) in general and upper respiratory tract infections (URTI) in particular are one of the most common acute conditions that cause the presentation to the doctor
The faster virucidal effect in high concentration was seen in the combination benzydamine hydrochloride (BH)/cetylpyridinium chloride (CPC) as throat lozenge when compared to CPC as free active substance
The present study was performed at the Institute of Microbiology and Immunology from Ljubljana, Slovenia, and the results were first published by Steyer et al in 2021, in the article “A Throat lozenge with Fixed Combination of Cetylpyridinium Chloride and Benzydamine Hydrochloride Has Direct Virucidal Effect on SARS-CoV-2” [7]
Summary
Respiratory tract infections (RTI) in general and upper respiratory tract infections (URTI) in particular are one of the most common acute conditions that cause the presentation to the doctor. Their presentation can be from a common cold to a life-threatening clinical form. Human coronaviruses are considered responsible for 10-15% of all upper respiratory tract infections in human population [3]. They generate a self-limited disease with upper respiratory tract symptoms. The novel coronavirus described in 2019, SARS-CoV-2, responsible for the COVID-19 disease, proved to be more aggressive with more than 246 million confirmed cases and more than 5 million deaths worldwide [4]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
